Hereditary Angioedema

Hereditary Angioedema

Global Hereditary Angioedema Market to Reach US$5.5 Billion by 2030

The global market for Hereditary Angioedema estimated at US$3.3 Billion in the year 2023, is expected to reach US$5.5 Billion by 2030, growing at a CAGR of 7.7% over the analysis period 2023-2030. C1 Esterase Inhibitors, one of the segments analyzed in the report, is expected to record a 8.2% CAGR and reach US$2.5 Billion by the end of the analysis period. Growth in the Selective Bradykinin B2 Receptor Antagonists segment is estimated at 6.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$889.5 Million While China is Forecast to Grow at 7.1% CAGR

The Hereditary Angioedema market in the U.S. is estimated at US$889.5 Million in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$849.3 Million by the year 2030 trailing a CAGR of 7.1% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.8% and 6.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.8% CAGR.

Global Hereditary Angioedema (HAE) Market - Key Trends & Drivers Summarized

What Is Hereditary Angioedema, and Why Is Treatment Demand Rising?

Hereditary angioedema (HAE) is a rare genetic disorder characterized by recurrent episodes of severe swelling, often affecting the skin, gastrointestinal tract, and airways. These attacks can be life-threatening, particularly when swelling affects the throat or airways, making effective management crucial. As awareness of HAE grows, more patients are receiving accurate diagnoses and treatments, increasing demand for therapies that can prevent and control these attacks. Early diagnosis and access to specialized treatments are essential for improving quality of life and reducing emergency interventions for HAE patients.

How Are New Therapeutics Improving HAE Management?

Advancements in HAE therapeutics, particularly preventive and acute treatment options, are transforming patient care. Therapies such as C1 esterase inhibitors, kallikrein inhibitors, and monoclonal antibodies specifically target the underlying causes of HAE, effectively reducing attack frequency and severity. Prophylactic treatments, in particular, enable patients to manage their condition proactively, preventing severe attacks and reducing hospital visits. These therapies are improving outcomes for HAE patients, allowing them to live with fewer disruptions and enhancing overall quality of life.

What Role Does Patient Support and Advocacy Play in Market Growth?

Patient support groups and advocacy organizations play a significant role in increasing awareness and driving access to HAE treatments. By educating patients and healthcare providers on the symptoms, risks, and available therapies, these organizations help patients seek timely treatment and participate in clinical trials. Advocacy efforts have also led to improved insurance coverage for expensive HAE treatments, making them more accessible. This community support is essential for advancing treatment options and ensuring that patients have the resources needed for effective HAE management.

What Drives the Growth of the Hereditary Angioedema Market?

The growth in the hereditary angioedema market is driven by increased awareness, advancements in targeted therapies, and strong patient advocacy efforts. Growing awareness enables earlier diagnosis and treatment, expanding the patient base for HAE therapeutics. Targeted therapies, including preventive options, are transforming HAE management, offering patients more effective and proactive treatment choices. Additionally, advocacy organizations are supporting access and awareness, helping to secure insurance coverage and enhance patient care. These factors collectively support market growth, as HAE management becomes increasingly accessible and effective for patients globally.

SCOPE OF STUDY:

The report analyzes the Hereditary Angioedema market in terms of US$ Million by the following Distribution Channel; Drug Class; Route of Administration, and Geographic Regions/Countries:

Segments:
Drug Class (C1 Esterase Inhibitors, Selective Bradykinin B2 Receptor Antagonists, Kallikrein Inhibitors, Other Drug Classes); Route of Administration (Subcutaneous Injections, Intravenous, Oral); Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Other Distribution Channels)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 46 Featured) -

• BioCryst Pharmaceuticals, Inc.
• CSL Ltd.
• iBio, Inc.
• Ionis Pharmaceuticals, Inc.
• Pharming Group NV
• Shire PLC

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.